主要先進国における全身性乾癬治療薬市場（～2020）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Overview 8
2.2 Epidemiology 9
2.3 Etiology, Co-morbidities and Risk Factors 10
2.3.1 Genetics 10
2.3.2 Psoriatic Arthritis 10
2.3.3 Mental Health Disorders 11
2.3.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 11
2.3.5 Infections 11
2.3.6 Köebner Phenomenon 12
2.3.7 Other Immune-mediated Diseases 12
2.4 Pathophysiology 12
2.5 Diagnosis 13
2.6 Treatment Options 13
2.6.1 Pharmacological Therapies 14
2.6.2 Non-pharmacological Therapies 15
2.6.3 Combination and Rotational Therapies 15
2.6.4 Quality of Life Assessments 16
2.7 Summary 16
3 Marketed Products 17
3.1 Overview 17
3.2 Methotrexate-based Products 17
3.3 Sandimmune/Neoral (cyclosporine/modified cyclosporine) – Novartis 18
3.4 Soriatane (acitretin) – Steifel Laboratories 19
3.5 Fumaderm (dimethyl fumarate and ethyl fumarate) – Biogen Idec 20
3.6 Humira (adalimumab) – Abbvie Inc. 21
3.7 Enbrel (etanercept) – Amgen Inc. 22
3.8 Remicade (infliximab) – Janssen Biotech 23
3.9 Stelara (ustekinumab) – Janssen Biotech 24
3.10 Marketed Products Heat Map 25
4 Pipeline 28
4.1 Overview 28
4.2 Pipeline Size and Distribution by Phase, Molecule Type and Program Type 29
4.3 Pipeline Distribution by Molecular Target 31
4.4 Clinical Trial Landscape 33
4.4.1 Clinical Trial Duration 33
4.4.2 Clinical Trial Size 37
4.5 Clinical trial failure rates 41
4.6 Primary and Secondary Endpoints 42
4.7 Summary of Psoriasis Clinical Trials 44
4.8 Promising pipeline molecules 44
4.8.1 Ixekizumab – Eli Lilly 44
4.8.2 Xeljanz (tofacitinib) – Pfizer 45
4.8.3 Brodalumab – Amgen 46
4.8.4 Apremilast – Celgene 47
4.8.5 Secukinumab – Alcon 48
4.9 Heat Map for Pipeline Products 48
5 Market Forecast to 2020 53
5.1 Overview 53
5.2 Global Market 53
5.3 North America 56
5.3.1 Treatment Usage Patterns 56
5.3.2 Annual Cost of Treatment 57
5.3.3 Market Size 59
5.4 Top Five EU Markets 60
5.4.1 Treatment Usage Patterns 60
5.4.2 Annual Cost of Treatment 61
5.4.3 Market Size 62
5.5 Japan 63
5.5.1 Treatment Usage Patterns 63
5.5.2 Annual Cost of Treatment 64
5.5.3 Market Size 65
5.6 Drivers and Barriers for the Systemic Psoriasis Therapeutics Market 66
5.6.1 Drivers 66
5.6.2 Barriers 66
6 Co-development and Licensing deals 68
6.1 Co-development Deals 68
6.1.1 Abbvie Enters into Co-development Agreement with Biotest for Tregalizumab 71
6.1.2 Lycera Enters into Research Agreement with Merck & Co. 71
6.1.3 LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases 71
6.1.4 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab 71
6.2 Licensing Deals 73
6.2.1 Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug 75
6.2.2 Foamix Enters into Licensing Agreement with Dr. Reddy’s Labs 75
6.2.3 Cipher Pharma Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch 75
6.2.4 Phenex Pharma Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 75
7 Appendix 76
7.1 All Pipeline Drugs by Phase 76
7.1.1 Discovery 76
7.1.2 Preclinical 78
7.1.3 Phase I 82
7.1.4 Phase II 84
7.1.5 Phase III 86
7.1.6 Undisclosed 87
7.2 Market Forecasts to 2020 87
7.2.1 Major Developed Markets 87
7.2.2 US 88
7.2.3 UK 88
7.2.4 France 89
7.2.5 Germany 89
7.2.6 Italy 90
7.2.7 Spain 90
7.2.8 Japan 91
7.2.9 Canada 91
7.3 Abbreviations 92
7.4 References 93
7.5 References for Heat Maps 98
7.5.1 Marketed Products 98
7.5.2 Pipeline products 98
7.6 Methodology 100
7.6.1 Secondary Research 100
7.6.2 Therapeutic Landscape 100
7.7 Contact Us 100
7.8 Disclaimer 101